A commercial launch gives this biotech something most clinical-stage names lack, while a regulatory decision is now on the calendar. The setup is less about one approval and more about what happens when several catalysts start stacking up.

Keep reading to see why the next few weeks could matter more than the latest quarter.

Retail

Bath & Body Works Inc. (NYSE: BBWI) trades near $18 after second-quarter revenue reached $1.51 billion and adjusted EPS came in at $0.62, well ahead of expectations. Management also raised full-year adjusted EPS guidance to $2.60 to $2.80 and lifted expected free cash flow to about $650 million.

The stock trades near 6.7 times the midpoint of adjusted earnings guidance. That $650 million cash-flow outlook equals nearly 18% of the current equity value, so you do not need a return to rapid sales growth for the valuation to start looking unusually compressed.

Operating income improved to $216 million from $157 million, while digital sales returned to growth. The company also pays an $0.80 annualized dividend, giving the shares a yield of roughly 4.4%.

Cash Flow Is Doing More Than Revenue

Sales are still declining, but stronger digital performance and cost control are supporting profitability while management works through weaker store traffic. Your margin of safety comes from the amount of cash the business can still produce at a valuation normally associated with much deeper operational stress.

Debt Explains Part of the Discount

Bath & Body Works carries roughly $3.9 billion of net debt, while Q2 earnings also benefited from about $80 million of tariff refunds. Q3 guidance points to another sales decline and sharply lower earnings, leaving the turnaround dependent on sustained cash generation rather than one unusually strong quarter.

Mining

Centerra Gold Inc. (NYSE: CGAU) trades near $24 after management highlighted a valuation gap at today’s Midwest IDEAS Conference. The company estimates its shares trade around 0.5 times net asset value, compared with roughly 0.7 times for peers.

The discount gets more interesting at the asset level. Management says Mount Milligan alone carries an estimated value roughly equal to Centerra’s entire current enterprise value of about $4.2 billion. You are therefore paying little implied value for Öksüt, Thompson Creek, Goldfield, Kemess, and the rest of the portfolio.

Centerra also holds $450.9 million of cash with no debt, while the stock trades near 7.6 times trailing earnings. Öksüt has generated roughly $780 million of free cash flow since June 2023, adding another operating asset behind the NAV calculation.

More Cash Could Arrive From Thompson Creek

The Thompson Creek molybdenum restart is targeting first production around mid-2027, potentially adding another source of free cash flow. Centerra can fund that development without leaning on a stretched balance sheet while still planning up to $200 million of buybacks this year.

Commodity Prices Still Drive the Asset Math

Centerra’s NAV depends heavily on gold, copper, and molybdenum prices, while new projects still carry execution risk. Strong metals markets have already lifted the shares, so your margin of safety rests on those underlying assets continuing to justify values well above the current market multiple.

Transportation

TORM plc (NASDAQ: TRMD) trades near $32.35 after reporting record second-quarter results and raising its 2026 outlook. EBITDA jumped to $416 million from $127 million, while net profit surged to $338 million from $59 million a year earlier.

Management now expects $1.0 billion to $1.2 billion of full-year EBITDA, putting the company near 3.8 times the midpoint at today’s enterprise value. The shares also sit below TORM’s reported $36.50 per-share NAV, giving you another valuation anchor beyond the unusually low earnings multiple.

TORM added a $2.40 quarterly dividend, equal to roughly 7.4% of the current share price in a single payment. Around 70% of 2026 earning days are already fixed at an average rate above $45,000 per day.

Fleet Value Backs Up the Earnings

TORM estimates its 97-vessel fleet is worth about $4.06 billion, helping support a consolidated NAV of $3.74 billion. With the stock roughly 11% below that level, your downside case is not based solely on whether today’s tanker profits continue indefinitely.

Tanker Rates Can Change the Math Quickly

Q2 freight rates benefited from Middle East disruptions and shifting oil trade flows, pushing fleetwide rates sharply higher. A normalization in tanker pricing would cut earnings and dividends, so the current four-times multiple needs to be viewed against a highly cyclical profit base rather than treated as permanently cheap.

Regeneron (NASDAQ: REGN)

Regeneron secured FDA approval for a therapy for fibrodysplasia ossificans progressiva, only the second approved treatment for that ultra-rare bone disorder, and is following it with a Phase 3 study in children and adolescents that extends the label beyond adults.

That approval sits on top of the Dupixent and Eylea HD franchises, which already fund one of the deepest late-stage platforms in large-cap biotech. What you are buying here is multiple independent shots on goal rather than a single binary event, with further regulatory decisions still queued for the back half.

That structure is what separates a diversified biotech from a lottery ticket, and it is why the setup reads cleaner than most names in the sector.

Ionis Pharmaceuticals (NASDAQ: IONS)

Ionis is running a commercial launch in severe hypertriglyceridemia while carrying a September PDUFA date for a separate rare disease candidate, which gives you a product on the market and a regulatory catalyst in the same name.

The cardiology conference in Munich at the end of this month brings one-year data plus early data on a next-generation follow-on with potential for far less frequent dosing. Recent open market buying by a director adds conviction to a setup that already has two dated events attached.

This is a mid-cap RNA platform with revenue rather than a pure clinical story, which changes the risk profile considerably.

Mirum Pharmaceuticals (NASDAQ: MIRM)

Mirum trades at a meaningful discount to a widely followed fair value estimate, and the pullback has widened that gap rather than closing it.

The rare disease growth story around its lead commercial product remains intact, with steady prescription execution rather than a single approval event driving results.

This suits you if you would rather own consistent commercial delivery than sit through binary regulatory outcomes. The cushion between price and estimated fair value is the margin you are being handed on entry.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any stocks you want me to check out.

Best Regards,
—Noah Zelvis
Undervalued Edge